Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Descriptive epidemiology of primary malignant and non-malignant central nervous tumors in Spain: Results from the Girona Cancer Registry (1994-2013).
Fuentes-Raspall R, Solans M, Roca-Barceló A, Vilardell L, Puigdemont M, Del Barco S, Comas R, García-Velasco A, Astudillo A, Carmona-Garcia MC, Marcos-Gragera R. Fuentes-Raspall R, et al. Among authors: del barco s. Cancer Epidemiol. 2017 Oct;50(Pt A):1-8. doi: 10.1016/j.canep.2017.07.005. Epub 2017 Jul 21. Cancer Epidemiol. 2017. PMID: 28738268
Pseudoprogression as an adverse event of glioblastoma therapy.
Balaña C, Capellades J, Pineda E, Estival A, Puig J, Domenech S, Verger E, Pujol T, Martinez-García M, Oleaga L, Velarde J, Mesia C, Fuentes R, Marruecos J, Del Barco S, Villà S, Carrato C, Gallego O, Gil-Gil M, Craven-Bartle J, Alameda F; GLIOCAT Group. Balaña C, et al. Among authors: del barco s. Cancer Med. 2017 Dec;6(12):2858-2866. doi: 10.1002/cam4.1242. Epub 2017 Nov 3. Cancer Med. 2017. PMID: 29105360 Free PMC article.
RNA sequencing and Immunohistochemistry Reveal ZFN7 as a Stronger Marker of Survival than Molecular Subtypes in G-CIMP-negative Glioblastoma.
Esteve-Codina A, Alameda F, Carrato C, Pineda E, Arpí O, Martinez-García M, Mallo M, Gut M, Dabad M, Tortosa A, Del Barco S, Capellades J, Puig J, Gallego O, Pujol T, Oleaga L, Gil-Gil M, de Quintana-Schmidt C, Valduvieco I, Martinez-Cardús A, Bellosillo B, Muñoz-Marmol AM, Esteve A, Domenech M, Camins A, Craven-Bartle J, Villa S, Marruecos J, Domenech S, de la Iglesia N, Balana C. Esteve-Codina A, et al. Among authors: del barco s. Clin Cancer Res. 2021 Jan 15;27(2):645-655. doi: 10.1158/1078-0432.CCR-20-2141. Epub 2020 Oct 26. Clin Cancer Res. 2021. PMID: 33106291
Non-pegylated liposomal doxorubicin combined with gemcitabine as first-line treatment for metastatic or locally advanced breast cancer. Final results of a phase I/II trial.
Del Barco S, Colomer R, Calvo L, Tusquets I, Adrover E, Sánchez P, Rifà J, De la Haba J, Virizuela JA. Del Barco S, et al. Breast Cancer Res Treat. 2009 Jul;116(2):351-8. doi: 10.1007/s10549-008-0218-8. Epub 2008 Oct 22. Breast Cancer Res Treat. 2009. PMID: 18941891 Clinical Trial.
A Comparison of RNA-Seq Results from Paired Formalin-Fixed Paraffin-Embedded and Fresh-Frozen Glioblastoma Tissue Samples.
Esteve-Codina A, Arpi O, Martinez-García M, Pineda E, Mallo M, Gut M, Carrato C, Rovira A, Lopez R, Tortosa A, Dabad M, Del Barco S, Heath S, Bagué S, Ribalta T, Alameda F, de la Iglesia N, Balaña C; GLIOCAT Group. Esteve-Codina A, et al. Among authors: del barco s. PLoS One. 2017 Jan 25;12(1):e0170632. doi: 10.1371/journal.pone.0170632. eCollection 2017. PLoS One. 2017. PMID: 28122052 Free PMC article.
54 results